Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
Mallinckrodt
Medtronic
Merck

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR DELATESTRYL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Delatestryl

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00399165 ↗ Oral Androgens in Man-4: (Short Title: Oral T-4) Completed GlaxoSmithKline Phase 1/Phase 2 2006-11-01 The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval
NCT00399165 ↗ Oral Androgens in Man-4: (Short Title: Oral T-4) Completed University of Washington Phase 1/Phase 2 2006-11-01 The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval
NCT00475501 ↗ 5-Alpha Reductase and Anabolic Effects of Testosterone Completed Endo Pharmaceuticals Phase 2 2007-01-01 The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.
NCT00475501 ↗ 5-Alpha Reductase and Anabolic Effects of Testosterone Completed Merck Sharp & Dohme Corp. Phase 2 2007-01-01 The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.
NCT00475501 ↗ 5-Alpha Reductase and Anabolic Effects of Testosterone Completed VA Office of Research and Development Phase 2 2007-01-01 The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.
NCT00965341 ↗ Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients Completed M.D. Anderson Cancer Center Phase 3 2009-09-01 The goal of this clinical research study is to learn if and how testosterone replacement therapy may affect fatigue in males with advanced cancer and low testosterone levels.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Delatestryl

Condition Name

Condition Name for Delatestryl
Intervention Trials
Prostate Cancer 2
Castration Resistant Metastatic Prostate Cancer 2
Walking, Difficulty 1
Benign Prostate Hypertrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Delatestryl
Intervention Trials
Prostatic Neoplasms 5
Hypogonadism 2
Spinal Injuries 1
Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Delatestryl

Trials by Country

Trials by Country for Delatestryl
Location Trials
United States 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Delatestryl
Location Trials
Washington 3
Maryland 3
California 2
District of Columbia 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Delatestryl

Clinical Trial Phase

Clinical Trial Phase for Delatestryl
Clinical Trial Phase Trials
Phase 3 2
Phase 2 7
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Delatestryl
Clinical Trial Phase Trials
Completed 5
Recruiting 4
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Delatestryl

Sponsor Name

Sponsor Name for Delatestryl
Sponsor Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Merck Sharp & Dohme Corp. 2
National Cancer Institute (NCI) 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Delatestryl
Sponsor Trials
Other 16
Industry 5
U.S. Fed 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Express Scripts
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.